export default function Ll37OverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        LL-37 is a real antimicrobial peptide your body already makes &mdash; produced by immune cells and skin to fight infections and heal wounds. The lab data is genuinely impressive. The community narrative around it (Lyme disease, biofilm clearing, immune optimization by injection) has run far ahead of what human clinical trials actually support. The dual-edge immunology &mdash; the same peptide that drives psoriasis and lupus pathology in autoimmune disease &mdash; is systematically underweighted in community discussions.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Immunity-Focused Wellness Person &mdash; Infection Resistance and Healing</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I read that LL-37 is something your body naturally makes to fight infections. If I inject more of it, will I get sick less often and heal faster?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Your body makes it for a reason &mdash; it really does kill pathogens</strong><br />LL-37 is not a fictional supplement ingredient. It&rsquo;s produced by your neutrophils, macrophages, and skin cells as part of your innate immune system&rsquo;s first-line response to infection. At high concentrations, it physically disrupts bacterial and fungal cell membranes. At lower concentrations, it modulates immune cell behavior and promotes wound healing. The mechanism is real, not invented.</li>
          <li><strong>Wound healing clinical trials do exist &mdash; this isn&rsquo;t purely theoretical</strong><br />There are Phase I and II clinical trials of LL-37 in wound healing contexts, primarily for chronic non-healing wounds applied topically or injected locally into the wound. These are actual human trials, not just animal studies. The evidence that LL-37 can support wound healing in specific, supervised clinical settings is real &mdash; just very different from self-administering it systemically for general immunity.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The fact that your body makes LL-37 doesn&rsquo;t mean injecting more of it is safe or equivalent &mdash; the body produces it in precise, localized amounts in response to specific signals. Pharmacological systemic doses are a fundamentally different thing. More importantly: LL-37 actively drives the inflammatory pathology in psoriasis, lupus, and rheumatoid arthritis. If you have any autoimmune condition, this is a hard stop. There are no human trials for the uses the community discusses (infection resistance, immune boosting by self-injection). Net: compelling biology, meaningful clinical gaps, real autoimmune risk that community narratives routinely omit.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; Immune Resilience and Rapid Wound Recovery</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;Heavy training suppresses immune function and I get sick every time I peak. Would LL-37 help, or is this not the right tool for exercise-induced immunosuppression?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The biology is directly relevant to high-load training contexts</strong><br />Intense training temporarily suppresses key components of immune function &mdash; the same neutrophils and epithelial immune cells that produce LL-37 naturally are affected by overtraining. The logic of supplementing what gets depleted has surface appeal. LL-37 also promotes skin and soft tissue healing through effects on blood vessel formation and tissue repair signals, which is relevant for athletes dealing with training-related injuries.</li>
          <li><strong>Injection site delivery to specific tissue is mechanistically relevant for localized healing</strong><br />Unlike systemic immune boosting (which has the autoimmune concerns), local injection of LL-37 near a healing injury has a more defensible mechanism &mdash; it&rsquo;s closer to what the wound healing trials actually studied. Some athletes use it specifically in this localized, injury-focused way rather than as a systemic immune compound.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Exercise-induced immunosuppression responds to sleep, periodization, adequate caloric intake, and stress management &mdash; the evidence base for these is real and deep. The evidence base for LL-37 as a systemic immune support compound in athletes is essentially nonexistent. Injection site reactions are common and can be significant &mdash; LL-37 is a membrane-disrupting peptide, which is exactly how it kills bacteria, and that property applies to mammalian cell membranes at high local concentrations. Source quality is a serious variable: impure LL-37 is a meaningful safety risk. Net: interesting hypothesis, no athlete-specific human data, meaningful source quality concern.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Immune System Biohacker &mdash; Cathelicidin Biology and the Dual-Edge Immunology</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to understand the cathelicidin system, specifically how LL-37&rsquo;s concentration-dependent antimicrobial versus immunomodulatory effects work, and what the autoimmune and cancer risk signals actually mean mechanistically.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why it&rsquo;s worth understanding</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The concentration-dependent mechanism is pharmacologically important to get right</strong><br />LL-37 is membrane-disrupting at high concentrations (direct antimicrobial effect) and immunomodulatory at lower concentrations (cytokine signaling, chemotaxis, dendritic cell maturation). The shift between these modes is not a clean binary &mdash; it&rsquo;s concentration-dependent in a way that makes the pharmacology of systemic injection genuinely complex. What you get at a given dose and at a given tissue concentration is not predictable from animal models in a straightforward way.</li>
          <li><strong>The cancer and autoimmune signals are mechanistically coherent, not incidental</strong><br />LL-37 is elevated in psoriatic lesions because it forms complexes with self-DNA that activate the immune system in a way that drives autoimmune inflammation &mdash; this is the actual pathogenic mechanism in psoriasis and has been clearly demonstrated. In cancer, LL-37 promotes some tumor types (gastric, ovarian, some lung adenocarcinoma subtypes) through angiogenesis and anti-apoptotic effects, while suppressing others. These are not rare edge cases &mdash; they reflect the biology of a peptide that activates innate immune responses, which have known dual-edge consequences in both autoimmune and tumor contexts.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">For a biohacker with no autoimmune disease and no cancer history, the risk profile is more manageable &mdash; but &ldquo;more manageable&rdquo; is not the same as &ldquo;characterized.&rdquo; What happens when a healthy person injects pharmacological systemic doses of LL-37 repeatedly has not been studied. The synthesis quality variable is real: LL-37&rsquo;s amphipathic helical structure is essential for activity and impure preparations don&rsquo;t just fail to work &mdash; they carry independent injection risks. If the goal is characterized immune support, Thymosin Alpha-1 has pharmaceutical-grade availability, approval in 35+ countries, and substantial human safety data by comparison. Net: the most pharmacologically interesting peptide in the innate immunity space; the most poorly characterized in terms of systemic safety for community use.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What LL-37 is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not validated for any of the community use cases (Lyme disease, biofilm clearing, systemic immune optimization) in human clinical trials</li>
              <li>Not safe in autoimmune disease &mdash; it actively drives psoriasis, lupus, and RA pathology; this is a hard stop</li>
              <li>Not automatically safe because it&rsquo;s endogenous &mdash; the body produces it locally and precisely; pharmacological systemic doses are a different thing</li>
              <li>Not a compound where source quality is a minor concern &mdash; impure LL-37 carries meaningful injection site and systemic reaction risk</li>
              <li>Not a first-choice immune support compound when Thymosin Alpha-1 exists with far more human safety data</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>The only human cathelicidin &mdash; a genuinely unique peptide in the innate immune system with no structural equivalent</li>
              <li>Wound healing Phase I/II trials do exist for topical and local injection contexts &mdash; it&rsquo;s not purely preclinical for every application</li>
              <li>The autoimmune and cancer dual-edge mechanism is one of the clearest examples in peptide biology of how context determines whether a compound helps or harms</li>
              <li>Concentration-dependent mode switching between antimicrobial and immunomodulatory functions is pharmacologically unusual and worth understanding</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
